Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis
| Autor: | Céline Phan, Nathalie Beneton, Juliette Delaunay, Ziad Reguiai, Claire Boulard, Anne-Claire Fougerousse, Elisa Cinotti, Marco Romanelli, Laure Mery-Bossard, Domitille Thomas-Beaulieu, Josiane Parier, François Maccari, Jean-Luc Perrot, Mireille Ruer-Mulard, Marie Bastien, Edouard Begon, Mahtab Samimi, Caroline Jacobzone, Nathalie Quiles-Tsimaratos, Vincent Descamps, Maud Steff, Paul Bilan, Annie Vermersch-Langlin, Mathilde Kemula, Emmanuelle Amazan, Ingrid Kupfer-Bessaguet, Anne-Caroline Cottencin, Francesca Prignano, Bulai Livideanu, Jeremy Gottlieb, Alain Beauchet, Emmanuel Mahé |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Acta Dermato-Venereologica, Vol 100, Iss 18, p adv00316 (2020) |
| Druh dokumentu: | article |
| ISSN: | 0001-5555 1651-2057 00015555 |
| DOI: | 10.2340/00015555-3678 |
| Popis: | Anti-interleukin-17 agents have recently been developed for the treatment of psoriasis. This study evaluated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practice. A multicentre, retrospective study was performed, involving psoriatic patients aged ≥65 years who had received an anti-interleukin-17 agent, including secukinumab, ixekizumab or brodalumab. A total of 114 patients were included: 72 received secukinumab, 35 ixekizumab, and 7 brodalumab. Treatment was stopped in 32 patients (28.9%), because of relapses in 14 patients (41.2%), primary failures in 11 patients (32.4%), or adverse events in 7 patients (20.6%). The 3 most frequently reported adverse events were injection site reactions (n = 4), oral candidiasis (n = 3), and influenza-like illness (n = 3). Regarding effectiveness, 80 patients (70%) reached a Physician Global Assessment score of 0/1, 6 months after treatment initiation. In conclusion, anti-interleukin-17 therapy appears to be an effective and safe therapeutic option for psoriasis treatment in patients aged ≥ 65 years. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|